Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma
- PMID: 21271301
- DOI: 10.1007/s12029-011-9257-1
Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors with a dismal prognosis. Although our understanding of the carcinogenesis of the disease increases continuously, no effective conservative therapeutic strategies exist. Therefore, novel targets have to be defined at the experimental level. Histone deacetylases (HDACs), especially the class I isoenzymes HDAC1, 2, and 3, are highly expressed in PDAC.
Conclusion: This article summarizes the expression and functions of HDAC isoenzymes in PDAC, with a special focus on their promoter-specific mode of action. Although we have gained some molecular insight into the HDAC function in PDAC, less is known about the relevance of histone acetyltransferases (HATs) in PDAC. As an example, we will summarize function of the HAT p300, for which promoter-specific functions were described recently. Increasing the molecular insights into the functions of the acetylating and deacetylating machineries in PDAC are important, since this will lead to novel rationally based therapeutic strategies in the future.
Similar articles
-
Targeting histone deacetylases in pancreatic ductal adenocarcinoma.J Cell Mol Med. 2010 Jun;14(6A):1255-63. doi: 10.1111/j.1582-4934.2009.00974.x. Epub 2009 Nov 19. J Cell Mol Med. 2010. PMID: 19929947 Free PMC article. Review.
-
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.Cancer Res. 2003 May 15;63(10):2624-30. Cancer Res. 2003. PMID: 12750289
-
Pan-cancer analysis of the transcriptional expression of histone acetylation enzymes in solid tumors defines a new classification scheme for gliomas.Front Immunol. 2025 Jan 21;15:1523034. doi: 10.3389/fimmu.2024.1523034. eCollection 2024. Front Immunol. 2025. PMID: 39906742 Free PMC article.
-
Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188676. doi: 10.1016/j.bbcan.2022.188676. Epub 2022 Jan 10. Biochim Biophys Acta Rev Cancer. 2022. PMID: 35016922 Review.
-
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.Mol Med Rep. 2020 Feb;21(2):822-832. doi: 10.3892/mmr.2019.10869. Epub 2019 Dec 6. Mol Med Rep. 2020. PMID: 31974610 Free PMC article.
Cited by
-
Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.Cancer Lett. 2013 Jan 28;328(2):212-21. doi: 10.1016/j.canlet.2012.10.005. Epub 2012 Oct 13. Cancer Lett. 2013. PMID: 23073473 Free PMC article. Review.
-
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.Oncol Ther. 2016;4(1):73-89. doi: 10.1007/s40487-016-0023-1. Epub 2016 Jun 10. Oncol Ther. 2016. PMID: 28261641 Free PMC article. Review.
-
Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations.J Enzyme Inhib Med Chem. 2024 Dec;39(1):2289355. doi: 10.1080/14756366.2023.2289355. Epub 2023 Dec 7. J Enzyme Inhib Med Chem. 2024. PMID: 38059332 Free PMC article.
-
MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.Oncogene. 2016 Mar 31;35(13):1609-18. doi: 10.1038/onc.2015.216. Epub 2015 Jun 29. Oncogene. 2016. PMID: 26119937 Review.
-
Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.Nat Commun. 2023 Dec 6;14(1):7791. doi: 10.1038/s41467-023-42178-6. Nat Commun. 2023. PMID: 38057326 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous